Subtopic Deep Dive
Mitochondrial Dysfunction in Neurodegeneration
Research Guide
What is Mitochondrial Dysfunction in Neurodegeneration?
Mitochondrial dysfunction in neurodegeneration refers to bioenergetic failure, impaired calcium handling, and defective mitophagy driven by genetic mutations like polyglutamine expansions in diseases such as Huntington's disease.
This subtopic links polyQ expansions to respiratory chain defects and ROS overproduction in genetic neurodegenerative disorders (Johri and Beal, 2012, 797 citations). Key studies demonstrate mTOR inhibition enhances autophagy to reduce polyglutamine toxicity in Huntington's models (Ravikumar et al., 2004, 2298 citations). Approximately 10 foundational papers from 2000-2012 establish these mechanisms, with over 8,000 combined citations.
Why It Matters
Mitochondrial therapies target energy deficits in familial Huntington's disease, as creatine supplementation stabilizes mitochondria and improves phenotypes in transgenic mice (Ferrante et al., 2000, 517 citations). ROS-mediated damage contributes to pathogenesis across Alzheimer's, Parkinson's, and Huntington's, offering shared therapeutic targets (Manoharan et al., 2016, 500 citations). Excitotoxicity via calcium dysregulation exacerbates neuronal loss, informing neuroprotective strategies (Dong et al., 2009, 1207 citations).
Key Research Challenges
Linking Genetics to Bioenergetics
PolyQ expansions impair respiratory chain function, but exact pathways remain unclear (Johri and Beal, 2012). Studies in YAC128 mice show striatal neuronal loss tied to energy failure (Slow, 2003, 791 citations). Quantifying mitochondrial deficits in human tissue poses technical barriers.
Mitophagy Defects in PolyQ Toxicity
mTOR inhibition boosts autophagy against polyQ aggregates, yet chronic induction risks neuronal stress (Ravikumar et al., 2004, 2298 citations). Mutant huntingtin fragments trigger cytochrome c release via proteasomal dysfunction (Jana, 2001, 454 citations). Selective mitophagy activators are lacking.
Translating Therapies to Humans
Creatine and HDAC inhibitors ameliorate HD phenotypes in mice but fail clinical trials (Ferrante et al., 2000; Ferrante et al., 2003, 517 and 684 citations). ROS scavengers show promise in models yet face bioavailability issues (Manoharan et al., 2016). Patient stratification by mitochondrial haplotypes is undeveloped.
Essential Papers
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease
Brinda Ravikumar, Corinne Vacher, Zdenek Berger et al. · 2004 · Nature Genetics · 2.3K citations
Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases
Xiao-xia Dong, Yan Wang, Zheng-Hong Qin · 2009 · Acta Pharmacologica Sinica · 1.2K citations
Mitochondrial Dysfunction in Neurodegenerative Diseases
Ashu Johri, M. Flint Beal · 2012 · Journal of Pharmacology and Experimental Therapeutics · 797 citations
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
Elizabeth Slow · 2003 · Human Molecular Genetics · 791 citations
An expanded CAG repeat is the underlying genetic defect in Huntington disease, a disorder characterized by motor, psychiatric and cognitive deficits and striatal atrophy associated with neuronal lo...
Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice
Robert J. Ferrante, James K. Kubilus, Junghee Lee et al. · 2003 · Journal of Neuroscience · 684 citations
The precise cause of neuronal death in Huntington's disease (HD) is unknown. Although no single specific protein-protein interaction of mutant huntingtin has emerged as the pathologic trigger, tran...
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Robert J. Ferrante, Ole A. Andreassen, Bruce G. Jenkins et al. · 2000 · Journal of Neuroscience · 517 citations
Huntington's disease (HD) is a progressive neurodegenerative illness for which there is no effective therapy. We examined whether creatine, which may exert neuroprotective effects by increasing pho...
The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Mini Review
Shanmugam Manoharan, Gilles J. Guillemin, Rajagopal Selladurai Abiramasundari et al. · 2016 · Oxidative Medicine and Cellular Longevity · 500 citations
Neurodegenerative diseases affect not only the life quality of aging populations, but also their life spans. All forms of neurodegenerative diseases have a massive impact on the elderly. The major ...
Reading Guide
Foundational Papers
Start with Ravikumar et al. (2004, 2298 citations) for autophagy-mTOR mechanism in polyQ models, then Johri and Beal (2012, 797 citations) for comprehensive mitochondrial overview, followed by Slow (2003, 791 citations) for YAC128 pathology.
Recent Advances
Manoharan et al. (2016, 500 citations) on ROS across diseases; Jiménez-Sánchez et al. (2016, 468 citations) on HD pathogenesis mechanisms.
Core Methods
YAC128 transgenic mice (Slow, 2003); creatine/phosphocreatine assays (Ferrante et al., 2000); mTOR inhibitors like rapamycin (Ravikumar et al., 2004); cytochrome c release detection (Jana, 2001).
How PapersFlow Helps You Research Mitochondrial Dysfunction in Neurodegeneration
Discover & Search
Research Agent uses citationGraph on Ravikumar et al. (2004) to map autophagy-mTOR links in 50+ polyQ papers, then exaSearch for 'mitochondrial dysfunction Huntington YAC128' uncovers Slow (2003) and similar models. findSimilarPapers expands to Johri and Beal (2012) for broad reviews.
Analyze & Verify
Analysis Agent applies readPaperContent to extract ROS data from Manoharan et al. (2016), verifies claims with CoVe against Johri and Beal (2012), and runs PythonAnalysis to plot citation trends or quantify CAG repeat effects from abstracts using pandas. GRADE grading scores evidence strength for mitophagy claims.
Synthesize & Write
Synthesis Agent detects gaps in mitophagy therapies post-Ravikumar (2004), flags contradictions between mouse models (Ferrante et al., 2000 vs. human translation). Writing Agent uses latexEditText for figure legends, latexSyncCitations for 20-paper bibliography, and latexCompile for neurodegeneration pathway diagrams via exportMermaid.
Use Cases
"Analyze ROS production rates in HD mouse models from key papers"
Research Agent → searchPapers('ROS Huntington mitochondrial') → Analysis Agent → runPythonAnalysis (pandas parsing of data from Manoharan 2016 and Johri 2012) → matplotlib plot of ROS levels vs. CAG repeats.
"Draft LaTeX review on polyQ mitophagy with citations"
Synthesis Agent → gap detection (autophagy therapies) → Writing Agent → latexEditText (intro section) → latexSyncCitations (Ravikumar 2004 et al.) → latexCompile → PDF with mitophagy pathway Mermaid diagram.
"Find code for YAC128 mitochondrial simulations"
Research Agent → searchPapers('YAC128 mitochondrial model') → Code Discovery → paperExtractUrls (Slow 2003) → paperFindGithubRepo → githubRepoInspect → R script for neuronal loss modeling.
Automated Workflows
Deep Research workflow scans 50+ papers on polyQ-mitochondria via searchPapers → citationGraph → structured report with GRADE-scored sections on bioenergetics. DeepScan applies 7-step CoVe to verify excitotoxicity claims (Dong et al., 2009) with runPythonAnalysis checkpoints. Theorizer generates hypotheses linking HDAC inhibition (Ferrante et al., 2003) to mitophagy from literature synthesis.
Frequently Asked Questions
What defines mitochondrial dysfunction in this subtopic?
Bioenergetic failure, calcium mishandling, and mitophagy defects from polyQ expansions like in Huntington's disease (Johri and Beal, 2012).
What are key methods studied?
mTOR inhibition for autophagy induction (Ravikumar et al., 2004); creatine for mitochondrial stabilization (Ferrante et al., 2000); YAC128 mouse models for striatal loss (Slow, 2003).
What are foundational papers?
Ravikumar et al. (2004, 2298 citations) on mTOR-autophagy; Johri and Beal (2012, 797 citations) on broad dysfunction; Dong et al. (2009, 1207 citations) on excitotoxicity.
What open problems exist?
Translating mouse therapies like creatine to humans; developing selective mitophagy activators; stratifying patients by mitochondrial genetics.
Research Genetic Neurodegenerative Diseases with AI
PapersFlow provides specialized AI tools for Neuroscience researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Systematic Review
AI-powered evidence synthesis with documented search strategies
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Mitochondrial Dysfunction in Neurodegeneration with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Neuroscience researchers